Compare Ascendis Pharma A/S (ASND) vs Global X Robotics and Artificial Intelligence ETF (BOTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Global X Robotics and Artificial Intelligence ETF — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Global X Robotics and Artificial Intelligence ETF trades at $35.95. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| ASND | BOTZ | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $41.63 |
52-Week Low | $163.32 | $31.99 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BOTZ trades at $36.91, up 0.76% today, but faces a bearish technical outlook with moving averages signaling strong selling pressure. The robotics and AI ETF benefits from growing investor interest in physical AI applications, with recent news highlighting humanoid robotics as the next trillion-dollar opportunity. However, key financial ratios remain unavailable for analysis.
The ETF's outlook is supported by accelerating robotics adoption but challenged by technical weakness. Investment opportunity lies in the structural shift toward automation, while risks include market volatility and concentrated sector exposure. The neutral oscillator readings suggest potential for near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →
